Despite the challenges created by the ongoing COVID-19 pandemic, UCB continues to grow our business in a sustainable way, achieving a strong financial performance in 2020, investing in research and development, and making progress on our commitments
Caring for Patients
In line with our purpose, UCB is committed to enabling people living with severe diseases, their caregivers and their families to live their best lives.
Caring through COVID-19
In 2020, delivering on our purpose of creating value for patients now and into the future became even more important, as COVID-19 spread around the world.
Communicating with care
Throughout this year we took steps to provide timely, clear and easily-accessible information to patients about the impact COVID-19 was having on our operations, the steps we were taking to mitigate these effects, and any potential repercussions on
Keeping patients safe
In March, we made the difficult decision to pause new patient recruitment into ongoing clinical studies and to postpone the launch of any new studies.
Securing supply chains
Together, our internal development and manufacturing capabilities and external network cover the full spectrum of Chemistry, Manufacturing and Controls (CMC) activities for small and large molecules – from process, analytical, formulation, device
Financial support for patients
In countries where patients may have needed additional financial support to cover the cost of our medicines, our Patient Assistance Programs (PAPs) were extended to help them in these exceptional circumstances and to ensure that patients who had
Playing our part in the wider response
We put our expertise and resources to work and advance COVID-19 basic research and treatment development in collaboration with various researchers and governments.
Digitalizing patient care
While 2020 was undoubtedly challenging, it also presented us with new and sometimes unexpected opportunities to pursue innovation in care and treatment.
Why we innovate
UCB’s approach to scientific innovation is a key area of our sustainability approach and underpins our commitment to make a positive impact for people living with severe diseases.